

## Oropouche Virus – Interim Fact Sheet

### Disease Agent:

- Oropouche virus (OROV)

### Disease Agent Characteristics:

- Family: Peribunyaviridae, genus Orthobunyavirus (La Crosse virus is another example)
- Virion morphology and size: Enveloped, 80-120 nm in diameter
- Nucleic acid: OROV is a negative-sense, single-stranded RNA virus with a spherical lipid-enveloped genome consisting of three single stranded RNA segments called large (L) medium (M) and small (S) of 6,852, 4,385 and 958 nucleotides respectively similar to La Crosse Virus.
  - There are four OROV genotypes but it is suggested that infection with any will provide immunity against future reinfection.
- Physicochemical properties: other Orthobunyaviruses are inactivated by a number of disinfectants including sodium hypochlorite (household bleach), hydrogen peroxide, peracetic acid and ethanol. Heat and gamma irradiation have also been used.

### Disease Names:

- Oropouche fever

### Priority Level:

- Scientific/Epidemiologic evidence regarding blood safety: Absent
- Public perception and/or regulatory concern regarding blood safety: Absent
- Public concern regarding disease agent: Absent in non-endemic areas. Moderate in endemic areas where recent reports suggesting vertical transmission and fetal injury *in utero* have increased this concern.

### Background:

- Discovered in Trinidad in 1955. As many as 500,000 infections may have occurred since, based on serological studies. It is certainly underrecognized due to limited clinical suspicion and access to diagnostics.
- OROV is an arthropod-borne orthobunyavirus found in South America and causes Oropouche fever, a febrile infection similar to dengue. It is the second most prevalent arthropod-borne viral disease in South America after dengue. The main vector is the biting midge *Culicoides paraensis*, with a range as far north as the United States (US) suggesting the potential for OROV infection to expand geographically. The sylvan transmission cycle is incompletely understood, and vertebrate hosts include both non-human primates and birds.
- OROV is a BSL level 2 or 3 pathogen, depending on the country. In the US it is level 2.

### Common Human Exposure Routes:

- Vector-borne
- No evidence for person-to-person spread before 2024 reports of vertical transmission *in utero*.

**Likelihood of Secondary Transmission:**

- Appears low but vertical transmission described during pregnancy at the case report level during 2024 transmission season in Brazil.

**At-Risk Populations:**

- Populations in endemic areas with exposure to vectors including travelers.

**Vector and Reservoir Involved:**

- *Culicoides paraensis*, a small biting fly or midge is the main vector but culex and other mosquitoes have also been implicated.
- In the urban cycle, *C. paraensis* is the primary vector which has been implicated in large epidemics affecting up to 100,000 patients.
- Possible reservoirs in the sylvatic cycle based largely on antibody studies include sloths, non-human primates, rodents and wild and domestic birds.
- Potential vectors are widespread globally but there is little information about their competence for OROV transmission.

**Blood Phase:**

- The virus was originally isolated from acute phase serum injected intracerebrally into mice. Small numbers of cases with virus isolation from blood have been reported subsequently.
- Subsequent references to viremia are largely confined to demonstration of RNA-emia but infectious virus is present during acute infection.
- The levels of both virus and RNA are highest early during symptomatic infection (peaking around day 2) and fall rapidly toward the end of the first week of illness. The virus may not be detectable by the time a patient seeks care.
- An appreciable rate of apparently asymptomatic infection ( $\approx 40\%$ ) raises the theoretical concern for transmission by blood and other substances of human origin.

**Survival/Persistence in Blood Products:**

- Unknown

**Transmission by Blood Transfusion:**

- Not reported to date from transfusion or transplantation

**Cases/Frequency in Population:**

- More than 30 epidemics have been recognized in Latin America and the Caribbean with the greatest number in Brazil. Autochthonous transmission has occurred in Peru, Panama, Colombia, Cuba, Bolivia, Venezuela, Haiti, French Guiana and Trinidad and Tobago.
- Extrapolation from serological studies suggest at least 500,000 infections had occurred by 2018.
- The prevalence of seroreactivity in affected regions can be as high as 20%.
- All genders and ages are affected.
- Since late 2023, Oropouche virus has caused large outbreaks in formerly endemic areas and new areas in South America. During 2024, more than 8000 infections have been reported, mainly from Brazil, during epidemiological weeks 1-29.
- 19 imported cases have been recognized in the EU (Spain, Italy and Germany), 18 after travel from Cuba and 1 from Brazil. There have been 11 in the US, all imported, as of 17 August 2024.

#### **Incubation Period:**

The incubation period is typically 3-8 days after exposure but there are reports extending to 14 days.

#### **Likelihood of Clinical Disease:**

Seroprevalence studies suggest many infections are either asymptomatic or not recognized as Oropouche fever.

#### **Primary Disease Symptoms:**

- Approximately 60% of infected individuals become symptomatic. The appreciable rate of apparently asymptomatic infection raises the theoretical concern for transmission by blood and other substances of human origin.
- Oropouche fever closely resembles dengue infection and other arboviral infections like chikungunya or Zika, and malaria. Requires an index of suspicion and specific testing to diagnose.
- Symptoms include fever, myalgia, arthralgia, headache and photophobia, nausea and vomiting, malaise and dizziness.
- Unusual manifestations include rash and hemorrhagic signs.
- Neurologic complications, including aseptic meningitis and encephalitis can occur (in perhaps as many as 4% of recognized infections), mainly in immunocompromised individuals, and Oropouche should be considered when these syndromes occur in endemic/epidemic areas with serological and virologic examination of CSF considered.
- Mild recurrent symptoms may occur for up to three weeks.
- Postinfectious weakness and asthenia may last several weeks.
- Systematic data on the impact of *in utero* exposure are lacking, but concern has been raised during 2024 when a woman with compatible symptoms presented at 30 weeks gestation with fetal demise. She had serologic evidence of OROV infection (in addition to chikungunya and dengue), and serum and placenta were OROV positive by RT-PCR. OROV RNA was detected in cord blood and organ tissues from the fetus, in the absence of dengue, chikungunya, Zika and Mayaro viruses.
- As of 1 August 2024, a miscarriage, 4 (retrospective) cases of microcephaly, and 3 more possible vertical transmissions associated with fetal death are under investigation in Brazil.

#### **Severity of Clinical Disease:**

- Oropouche fever is generally relatively mild and self-limiting.
- More severe (e.g., CNS) illness can occur, especially in the presence of immunocompromise.
- The relationship to fetal injury and its spectrum is not clear.

**Mortality:**

- Mortality is highly unusual. During the current epidemic in South America, from reporting weeks 1 through 29, 2 deaths among 8078 cases have been reported, and these may be the first deaths attributed to OROV since its discovery.

**Chronic Carriage:**

- None

**Treatment Available/Efficacious:**

- Supportive; no specific anti-viral treatment is available

**Agent-specific Screening Question(s):**

- No specific question is in use.
- No sensitive or specific question is feasible.

**Laboratory Test(s) Available:**

- No FDA-licensed blood donor screening tests exist for OROV.
  - Diagnostic studies are available mainly after consultation with state and local public health laboratories.
- OROV is occasionally isolated in cell culture from the blood and/or CSF of symptomatic cases. Culturable virus is generally gone by the end of the first week of illness.
- Serological tests include EIAs (IgM and IgG) generally detecting antibodies to nucleocapsid antigens, PRNT, and immunoblots from blood or CSF. They are generally reactive from the 5<sup>th</sup> day after symptom onset. Cross-reactivity with related viruses can be an issue.
- Nucleic acid amplification assays are sensitive and specific and are the primary tests being used in epidemic areas.

**Currently Recommended Donor Deferral Period:**

- No FDA Guidance or AABB Standard exists.
- Prudent practice would be to defer until fully recovered.

**Impact on Blood Availability:**

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

**Impact on Blood Safety:**

- Agent-specific screening question(s): Not applicable
- Laboratory test(s) available: Not applicable

**Leukoreduction Efficacy:**

- Unknown

**Pathogen Reduction Efficacy for Plasma Derivatives:**

- Multiple pathogen reduction steps used in the fractionation process have been shown to be robust in removal of enveloped viruses.

**Other Prevention Measures:**

- There is no licensed vaccine.
- Arthropod avoidance (e.g. repellants and barriers)
- No effective vector control measures have been described for the primary *Culicoides* vector.

**Suggested Reading:**

1. Anderson CR, Spence L, Downs WG, Aitken TH. Oropouche virus: a new human disease agent from Trinidad, West Indies. *Am J Trop Med Hyg.* 1961. 10:574-8.
2. Cardoso BF, Serra OP, Heinen LB, Zuchi N, Souza VC, Naveca FG, Santos MA, Shlessarenko RD. Detection of Oropouche virus segment S in patients and in *Culex quinquefasciatus* in the state of Mato Grosso, Brazil. *Mem Inst Oswaldo Cruz.* 2015. Sep;110(6):745-54.
3. CDC. Clinical overview of Oropouche virus disease. 2024. At <https://www.cdc.gov/oropouche/hcp/clinical-overview/index.html>. Accessed 16 August 2024.
4. CDC. Increased Oropouche virus activity and associated risk to travelers. 2024. At <https://emergency.cdc.gov/han/2024/han00515.asp>. Accessed 17 August 2024.
5. CDC. Traveler's Health: Oropouche in the Americas. 2024. At <https://wwwnc.cdc.gov/travel/notices/level1/oropouche-the-americas>. Accessed 16 August 2024.
6. Ciuderis KA, Berg MG, Perez LJ, Hadji A, Perez-Restrepo LS, Aristizabal LC, Forberg K, Yamaguchi J, Cardona A, Weiss S, Qiu X, Hernandez-Ortiz JP, Averhoff F, Cloherty GA, Osorio JE. Oropouche virus as an emerging cause of acute febrile illness in Colombia. *Emerg Microbes Infect.* 2022. 11(1):2645-2657.
7. European Centre for Disease Prevention and Control. Oropouche virus disease cases imported into the European Union – 9 August 2024. Stockholm; ECDC: 2024. At: <https://www.ecdc.europa.eu/sites/default/files/documents/TAB-Oropouche-august-2024.pdf>. Accessed 18 August 2024.

8. Files MA, Hansen CA, Herrera VC, Schindewolf C, Barrett ADT, Beasley DWC, Bourne N, Milligan GN. Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development. *NPJ Vaccines*. 2022. 7(1):38.
9. Moutinho S. Little-known virus surging in Latin America may harm fetuses. *Science*. 2024. 385:355.
10. PAHO. Epidemiological Alert Oropouche in the Region of the Americas: vertical transmission event under investigation in Brazil - 17 July 2024. At <https://www.paho.org/en/documents/epidemiological-alert-oropouche-region-americas-vertical-transmission-event-under>. Accessed 15 August 2024.
11. PAHO. Epidemiological Alert: Oropouche in the Region of the Americas, 1 August 2024. Washington, D.C.: PAHO/WHO; 2024. At <https://www.paho.org/en/documents/epidemiological-alert-oropouche-region-americas-1-august-2024>. Accessed 19 August 2024.
12. PAHO. Q&A—Oropouche fever. 2024. At <https://www.paho.org/en/news/24-7-2024-qa-oropouche-fever>. Accessed 15 August 2024.
13. Romero-Alvarez D, Escobar LE. Oropouche fever, an emergent disease from the Americas. *Microbes Infect*. 2018. 20(3):135-146.
14. Sakkas H, Bozidis P, Franks A, Papadopoulou C. Oropouche Fever: A Review. *Viruses*. 2018. 10(4):175.